15 Breast Cancer Clinical Trials in Denver, CO (2026)

Q: How do I join a clinical trial in Denver?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you.

Recruiting Breast Cancer Studies in Denver

NCT06312176Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone rece...

Denver, COPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07085767Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for...

Denver, COPHASE31,000 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT03995082Recruiting

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey

The purpose of this research protocol is to measure Patient Reported Outcome Measures (PROMs) in breast cancer patients. PROM results will be provided to patients and providers and the investigators w...

Denver, CONA925 participantsUniversity of Colorado, Denver

View Study Details

NCT01503190Recruiting

The Immune System's Response to Young Women's Breast Cancer

This study plans to learn more about the immune system's response to breast cancer in young women....

Denver, CO800 participantsUniversity of Colorado, Denver

View Study Details

NCT06103864Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemot...

Denver, COPHASE3625 participantsAstraZeneca

View Study Details

NCT06435429Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the...

Denver, COPHASE3550 participantsJazz Pharmaceuticals

View Study Details

NCT06016738Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whos...

Denver, COPHASE3510 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06377852Recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effec...

Denver, COPHASE3500 participantsAmerican Society of Clinical Oncology

View Study Details

NCT06926868Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physi...

Denver, COPHASE2500 participantsBristol-Myers Squibb

View Study Details

NCT07029399Recruiting

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tum...

Denver, COPHASE1361 participantsNiKang Therapeutics, Inc.

View Study Details

NCT07102381Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-st...

Denver, COPHASE2125 participantsJazz Pharmaceuticals

View Study Details

NCT07007559Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in partic...

Denver, COPHASE2120 participantsALX Oncology Inc.

View Study Details

NCT06999187Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refra...

Denver, COPHASE196 participantsDren Bio

View Study Details

NCT06813053Recruiting

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

This is a study to assess the feasibility and acceptability of a novel decision aid (DA) in a newly diagnosed, early-stage breast cancer population. Insights gained from patient feedback and the imple...

Denver, CONA60 participantsUniversity of Colorado, Denver

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

Denver, COPHASE127 participantsVironexis Biotherapeutics Inc.

View Study Details

About Breast Cancer Clinical Trials in Denver

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 15 breast cancer clinical trials recruiting participants in Denver, CO. These studies are seeking a combined 7,399 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Olema Pharmaceuticals, Inc., University of Colorado, Denver and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Denver — FAQ

Are there breast cancer clinical trials in Denver?

Yes, there are 15 breast cancer clinical trials currently recruiting in Denver, CO. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Denver?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.

Are clinical trials in Denver free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 15 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 21, 2026 from ClinicalTrials.gov